Menu

There is probably no dividend cut on the horizon for these healthcare companies.

2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗

Today 13:20 EDT

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

Topics Artificial Intelligence

Uncover the latest developments among dow jones stocks in today's session. ↗

Today 12:40 EDT

Via Chartmill

3 Healthcare Dividend Stocks Offering More Than Just Income ↗

Today 11:35 EDT

Via MarketBeat

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Today 8:15 EDT

SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗

Today 6:50 EDT

SHCD is missing some of the healthiest dividend stocks.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Topics ETFs Stocks

3 Cash-Producing Stocks with Open Questions

Today 0:33 EDT

Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks

Which dow jones stocks are moving on Tuesday? ↗

September 29, 2026

Via Chartmill

September 28, 2026

Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Topics Artificial Intelligence Intellectual Property

September 28, 2026

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Friday's session: top gainers and losers in the dow jones index ↗

September 25, 2026

Via Chartmill

September 25, 2026

Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

Stay informed with the top movers within the dow jones index on Thursday. ↗

September 24, 2026

Via Chartmill

Thursday's session: top gainers and losers in the dow jones index ↗

September 24, 2026

Via Chartmill

September 24, 2026

From Merck & Co.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Wednesday's session: top gainers and losers in the dow jones index ↗

September 23, 2026

Via Chartmill

Stay informed with the top movers within the dow jones index on Wednesday. ↗

September 23, 2026

Via Chartmill

3 Healthcare Stocks with Warning Signs

September 23, 2026

U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Tuesday's session: top gainers and losers in the dow jones index ↗

September 22, 2026

Via Chartmill

Uncover the latest developments among dow jones stocks in today's session. ↗

September 22, 2026

Via Chartmill

September 22, 2026

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗

Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗

September 22, 2026

Via Chartmill

Topics Artificial Intelligence

September 22, 2026

Investors buying this biotech stock now will get its pipeline essentially for free.

Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% in...

3 Reasons to Sell MRK and 1 Stock to Buy Instead

September 22, 2026

Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan

Topics Stocks

These dow jones stocks are moving in today's session ↗

September 21, 2026

Via Chartmill

Discover which dow jones stocks are making waves on Monday. ↗

September 21, 2026

Via Chartmill

September 21, 2026

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

September 18, 2026

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV

September 18, 2026